



May 10, 2017

## **Alder BioPharmaceuticals® to Present at the Bank of America Merrill Lynch 2017 Health Care Conference**

BOTHELL, Wash., May 10, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2017 Health Care Conference at 10:40 a.m. PT (1:40 p.m. ET) on Wednesday, May 17, 2017 in Las Vegas, NV. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.

A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder's website at <http://www.alderbio.com>, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.

Link: <http://www.veracast.com/webcasts/baml/healthcare2017/id46205172515.cfm>

### **About Alder BioPharmaceuticals, Inc.**

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit <http://www.alderbio.com>.

#### Media Contact:

David Schull

Russo Partners, LLC

(212) 845-4271

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

#### Investor Relations Contact:

David Walsey

Alder BioPharmaceuticals, Inc.

(425) 408-8032

[ir@alderbio.com](mailto:ir@alderbio.com)